Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Washington Post Details Six Senators To Watch On Health Care; Politics Of Fear Gain Prominence
The battle over health care reform will happen in the Senate, even though President Obama keeps getting all the attention, The Washington Post"s The Fix reports.
generic viagra online
Copy Number Analysis Indicates Monoclonal Origin Of Lethal Metastatic Prostate Cancer
BERKELEY, CA (UroToday.com) - I was trained and board certified as a urologist (University of Virginia) and pathologist (Cornell and UVA) and arrived at Johns Hopkins in 1991 to do a research fellowship with Dr. William B. Isaacs, funded by the American Foundation for Urologic Disease (now the AUA Foundation).
plastic surgery before after
News of the day
Infants Experience Errors In Heart Meds Most Often
Infants and young children treated with heart drugs get the wrong dose or end up on the wrong end of medication errors more often than older children, according to research led by the Johns Hopkins Children"s Center published July 6 in Pediatrics.
Oncology

Xcelience Reduces Time To Phase I Studies By 17 Weeks Using API Into Capsule Services

Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA). API into Capsule projects are on average completed 45 percent faster than traditional formulation efforts, and in some specific cases we have saved our clients as much as 17 weeks. "Today"s molecule is under pressure," says Derek Hennecke, CEO and President. "We need to work smarter with clients to make the best choices, often with limited material. One of the best decisions we made was to put our money on Xcelodose ®. We were the first CRO in North America to do so, we"ve built up industry leading expertise, and this month we are proud to announce our 100th GMP batch." "Our defined API into Capsule program is a true differentiator, but not the only one," adds V.P. Randall H. Guthrie. "Xcelience combines decades of drug development experience, state-of-the-art equipment, a strong audit history, and sound financial management to deliver solutions that enable our clients to rely on us to accelerate drug development programs and meet critical milestones." Xcelience is also announcing a strategic expansion focused on areas of proven strength: low weight fills and potent compounds for API into capsule, continued expansion and growth of its formulation development team, implementation of UPLC analytical capability, investment in x-ray diffraction for preformulation activities, and blister packaging in support of client"s clinical supply needs. Development of the purpose-built Grace Street expansion continues as planned. Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience"s unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. Xcelience LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009